Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State

Inclusion Criteria: * Men and women ages 18 to 45 inclusive * Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations * Body Mass Index (BMI) of 18 to 32 kg/m2, inclusive. BMI = weight (kg)/ \[height (m)\]2 Exclusion Criteria: * WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 8 weeks after the last dose of investigational product * Any significant acute or chronic medical illness * Current or recent (within 3 months) gastrointestinal disease * Any major surgery within 4 weeks of study drug administration * Glucosuria at screening * Abnormal liver functions tests (ALT, AST or total bilirubin \> 10% above ULN) * Presence of edema on physical exam * History of diabetes mellitus * History of heart failure * History of renal insufficiency * History of chronic or recurrent UTI (defined as 3 occurrences per year) or UTI in the past 3 months * History of recurrent (defined as 3 occurrences per year) or recent vulvovaginal mycotic infections * Estimated creatinine clearance (ClCR) of \< 80 mL/min using the Cockcroft Gault formula * History of allergy or intolerance to metformin or other similar agents